Once NT-proBNP is included, only hsTnT moderately further improved risk stratification in this group of chronic HF with reduced ejection fraction patients with moderate anemia. NT-proBNP and hsTnT far outperform other emerging biomarkers in prediction of adverse outcome. This evidence concerns the gene NPPB and anemia (phenotype).